文献速递真实世界研究与卫生经济流行病学与生物统计

世界卫生组织基本药物示范目录的国家层面适配与实施:定性证据综合

National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis.
PubMed 文献 · PLoS Med · 2022-03-11

该定性证据综合检索10个数据库至2021年10月,纳入23项定性研究,覆盖30个场景,识别影响WHO基本药物示范目录国家层面适配与实施的因素。研究发现围绕国家药物目录的制度设计、治理与领导力,管理证据以支持目录更新的能力,以及目录通过改变供方激励对采购和处方的影响三个主题。作者认为应加大对实施路径各阶段所需流程与机构的投入,并需进一步研究目录与采购、药物可获得性之间的关联。

要点

  • 国家药物目录的制度设计、治理与领导力对WHO基本药物示范目录的国家适配与实施至关重要。
  • 管理证据以支持目录更新的能力,包括全球证据情境化、利用本地数据与专家知识及评估预算影响,是关键因素。
  • 国家药物目录通过改变供方激励、链接筹资采购系统及捐赠方影响,对采购和处方行为产生作用。

核心结论

  • 该定性证据综合强调WHO基本药物示范目录实施固有的复杂性与相互依赖性。
  • 为最大化国家药物目录的价值,应加大对支持从全球规范到调整处方行为各实施阶段所需流程与机构的投入。
  • 进一步研究国家药物目录与采购、药物可获得性之间的关联,将为优化目录实施提供更多见解。

研究设计与样本

  • 定性证据综合,检索10个数据库(包括CINAHL、Embase、Ovid MEDLINE、Scopus和Web of Science)至2021年10月。
  • 纳入聚焦国家层面实施WHO基本药物示范目录的原始定性研究。
  • 筛选1567条唯一题录,审阅183篇全文,最终纳入来自30个场景的23项研究。
  • 未收集非英语研究及灰色文献中利益相关者的经验与看法。
  • 使用CASP工具评价论文,并使用GRADE-CERQual评估对研究发现的信心。

主要发现

  • 研究发现围绕三个主要观点:国家药物目录的制度设计、治理与领导力,特别是透明度、协调能力、立法机制、管理地区差异和临床指导的考虑。
  • 管理证据以支持国家药物目录更新的能力,包括全球证据情境化、利用本地数据与专家知识及评估预算影响的流程,其中本地相关的成本效果信息发挥重要作用。
  • 国家药物目录通过改变供方激励,经由与筹资和采购系统的链接及捐赠方影响,对采购和处方产生影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未收集非英语研究及灰色文献中利益相关者的经验与看法。
  • 进一步研究国家药物目录与采购、药物可获得性之间的关联将提供更多见解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization Model List of Essential Medicines (WHO EML) has played a critical role in guiding the country-level selection and financing of medicines for more than 4 decades. It continues to be a relevant evidence-based policy that can support universal health coverage (UHC) and access to essential medicines. The objective of this review was to identify factors affecting adaptation and implementation of WHO EML at the national level. METHODS AND FINDINGS: We conducted a qualitative evidence synthesis by searching 10 databases (including CINAHL, Embase, Ovid MEDLINE, Scopus, and Web of Science) through October 2021. Primary qualitative studies focused on country-level implementation of WHO EML were included. The qualitative findings were populated in the Supporting the Use of Research Evidence (SURE) framework, and key themes were identified through an iterative process. We appraised the papers using the Critical Appraisal Skills Programme (CASP) tool and assessed our confidence in the findings using the Grading of Recommendations Assessment, Development and Evaluation working group-Confidence in Evidence from Reviews of Qualitative research (GRADE-CERQual). We screened 1,567 unique citations, reviewed 183 full texts, and included 23 studies, from 30 settings. Non-English studies and experiences and perceptions of stakeholders published in gray literature were not collected. Our findings centered around 3 main ideas pertaining to national adaptation and implementation of WHO EML: (1) the importance of designing institutions, governance, and leadership for national medicines lists (NMLs), particularly the consideration of transparency, coordination capacity, legislative mechanisms, managing regional differences, and clinical guidance; (2) the capacity to manage evidence to inform NML updates, including processes for contextualizing global evidence, utilizing local data and expert knowledge, and assessing budget impact, to which locally relevant cost-effectiveness information plays an important role; and (3) the influence of NML on purchasing and prescribing by altering provider incentives, through linkages to systems for financing and procurement and donor influence. CONCLUSIONS: This qualitative evidence synthesis underscores the complexity and interdependencies inherent to implementation of WHO EML. To maximize the value of NMLs, greater investments should be made in processes and institutions that are needed to support various stages of the implementation pathway from global norms to adjusting prescribed behavior. Moreover, further research on linkages between NMLs, procurement, and the availability of medicines will provide additional insight into optimal NML implementation. PROTOCOL REGISTRY: PROSPERO CRD42018104112.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Peacocke EF, Myhre SL, Foss HS, et al. National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis. PLoS Med. 2022. PMID: 35275938. doi:10.1371/journal.pmed.1003944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。